• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

膀胱癌样本的处理与报告：病理学家的观点

Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View.

作者信息

Mazzucchelli Roberta, Marzioni Daniela, Tossetta Giovanni, Pepi Laura, Montironi Rodolfo

机构信息

Section of Pathological Anatomy, Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy.

Departement of Experimental and Clinical Medicine, Università Politecnica delle Marche, Ancona, Italy.

出版信息

Front Surg. 2021 Dec 2;8:754741. doi: 10.3389/fsurg.2021.754741. eCollection 2021.

DOI:10.3389/fsurg.2021.754741
PMID:34926567
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8674620/
Abstract

The aim of this narrative review is to provide adequate information on handling and reporting of the bladder cancer samples to improve the closely collaboration between pathologists and urologists. The main (but not exclusive) research tool used was PubMed and 87 references were selected and quoted in the text. We have considered handling of biopsies, transurethral resection (TUR), and cystectomy specimens to summarize the different methods of sampling and the related issues. Moreover, we considered and discussed the main prognostic factors, such as histological tumor type, grade, and stage of bladder cancer, that should be described in the pathological report. In addition, critical issues encountered in the interpretation of histological samples were discussed.

摘要

本叙述性综述的目的是提供有关膀胱癌样本处理和报告的充分信息，以改善病理学家和泌尿科医生之间的密切合作。主要（但非唯一）使用的研究工具是PubMed，文中选择并引用了87篇参考文献。我们考虑了活检、经尿道切除术（TUR）和膀胱切除术标本的处理，以总结不同的采样方法及相关问题。此外，我们考虑并讨论了病理报告中应描述的主要预后因素，如膀胱癌的组织学肿瘤类型、分级和分期。此外，还讨论了组织学样本解读中遇到的关键问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1693/8674620/03f34725c65e/fsurg-08-754741-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1693/8674620/7b8cb7298bab/fsurg-08-754741-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1693/8674620/73b436ef5542/fsurg-08-754741-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1693/8674620/03f34725c65e/fsurg-08-754741-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1693/8674620/7b8cb7298bab/fsurg-08-754741-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1693/8674620/73b436ef5542/fsurg-08-754741-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1693/8674620/03f34725c65e/fsurg-08-754741-g0003.jpg

相似文献

1
Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View.膀胱癌样本的处理与报告：病理学家的观点
Front Surg. 2021 Dec 2;8:754741. doi: 10.3389/fsurg.2021.754741. eCollection 2021.
2
Prognostic impact of histological discordance between transurethral resection and radical cystectomy.经尿道切除术与根治性膀胱切除术之间组织学不一致的预后影响。
BJU Int. 2024 Aug;134(2):207-218. doi: 10.1111/bju.16296. Epub 2024 Feb 12.
3
The pathologist's role in multidisciplinary management of bladder cancer.
Ann Clin Lab Sci. 1994 Nov-Dec;24(6):481-8.
4
Comparison of pathological staging and grading of urothelial bladder carcinoma in post-transurethral resection and post-radical cystectomy specimens.经尿道膀胱肿瘤电切术和根治性膀胱切除术后标本中尿路上皮膀胱癌的病理分期和分级比较。
Pol J Pathol. 2014 Dec;65(4):305-12. doi: 10.5114/pjp.2014.48192.
5
Impact of second opinion pathology in the definitive management of patients with bladder carcinoma.二次病理会诊意见对膀胱癌患者最终治疗的影响。
Cancer. 2001 Apr 1;91(7):1284-90.
6
The pathologist's role in the detection of rare variants of bladder cancer and analysis of the impact on incidence and type detection.病理学家在膀胱癌罕见变异的检测以及对发病率和类型检测影响的分析中的作用。
Minerva Urol Nefrol. 2018 Dec;70(6):594-597. doi: 10.23736/S0393-2249.18.03175-2. Epub 2018 Sep 10.
7
A contemporary update on pathology reporting for urinary bladder cancer.膀胱癌病理报告的当代更新。
Int J Immunopathol Pharmacol. 2012 Jul-Sep;25(3):565-71. doi: 10.1177/039463201202500302.
8
p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy?膀胱T1G3移行细胞癌活检标本中的p53免疫反应性——指导是否进行膀胱切除术决策的有用参数？
Eur J Cancer. 2000 Mar;36(5):610-4. doi: 10.1016/s0959-8049(99)00325-1.
9
Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.经尿道膀胱肿瘤切除术和根治性膀胱切除术配对标本中尿路上皮癌的淋巴管浸润情况。
J Urol. 2008 Nov;180(5):1928-32; discussion 1932. doi: 10.1016/j.juro.2008.07.056. Epub 2008 Sep 17.
10
Staging error in the bladder tumor: the correlation between stage of TUR and cystectomy.
Int Urol Nephrol. 2001;33(4):627-9. doi: 10.1023/a:1020553812554.

引用本文的文献

1
The Handling and Sampling of Radical Cystectomy Specimens: A Standardized Approach for Pathological Evaluation.根治性膀胱切除术标本的处理与取样：病理评估的标准化方法
Methods Protoc. 2025 Apr 5;8(2):35. doi: 10.3390/mps8020035.
2
Bladder Cancer and Artificial Intelligence: Emerging Applications.膀胱癌与人工智能：新兴应用
Urol Clin North Am. 2024 Feb;51(1):63-75. doi: 10.1016/j.ucl.2023.07.002. Epub 2023 Aug 25.
3
Recent advances in three-dimensional ultrasound virtual cystoscopy in modeling and local staging for urothelial carcinoma with histopathological correlation: a cohort prospective study.

本文引用的文献

1
Tumor Resection, Optical Molecular Imaging, and the Potential Synergy of the Combination of the Two Techniques in Bladder Cancer.肿瘤切除术、光学分子成像以及这两种技术联合应用于膀胱癌的潜在协同作用。
Front Oncol. 2021 Mar 16;11:638083. doi: 10.3389/fonc.2021.638083. eCollection 2021.
2
Stage T1 bladder cancer: diagnostic criteria and pitfalls.T1 期膀胱癌：诊断标准和误区。
Pathology. 2021 Jan;53(1):67-85. doi: 10.1016/j.pathol.2020.09.014. Epub 2020 Nov 3.
3
An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting.
三维超声虚拟膀胱镜检查在尿路上皮癌建模和局部分期中的最新进展及其与组织病理学的相关性：一项队列前瞻性研究
Ann Med Surg (Lond). 2023 Sep 27;85(11):5365-5371. doi: 10.1097/MS9.0000000000001345. eCollection 2023 Nov.
4
Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies.透明细胞肾细胞癌治疗的最新进展：新型生物标志物与靶向治疗
Cancers (Basel). 2023 Jun 16;15(12):3207. doi: 10.3390/cancers15123207.
5
Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective.非肌层浸润性膀胱癌的精准诊断与治疗——临床视角
Front Oncol. 2023 Jan 31;13:1042552. doi: 10.3389/fonc.2023.1042552. eCollection 2023.
6
Pathology of Urologic Cancers.泌尿系统癌症病理学
Cancers (Basel). 2022 Aug 1;14(15):3751. doi: 10.3390/cancers14153751.
7
Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes.尿路上皮癌组织学变体概述：当前趋势及治疗结果的叙述性综述
Transl Androl Urol. 2022 Jun;11(6):877-901. doi: 10.21037/tau-22-43.
国际协作共识声明：整块切除膀胱肿瘤，包含两项系统评价、两轮德尔菲调查和一次共识会议。
Eur Urol. 2020 Oct;78(4):546-569. doi: 10.1016/j.eururo.2020.04.059. Epub 2020 May 8.
4
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging.pT1 高级别膀胱癌：组织学标准、浸润评估中的陷阱及亚分期。
Virchows Arch. 2020 Jul;477(1):3-16. doi: 10.1007/s00428-020-02808-6. Epub 2020 Apr 15.
5
En bloc resection of bladder tumors: indications, techniques, and future directions.膀胱肿瘤整块切除术：适应证、技术和未来方向。
Curr Opin Urol. 2020 May;30(3):421-427. doi: 10.1097/MOU.0000000000000737.
6
Plasmacytoid Variant Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis of Clinicopathological Features and Survival Outcomes.膀胱浆细胞样变异型尿路上皮癌：临床病理特征和生存结局的系统评价和荟萃分析。
J Urol. 2020 Aug;204(2):215-223. doi: 10.1097/JU.0000000000000794. Epub 2020 Jan 31.
7
Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).膀胱癌-膀胱切除术、膀胱前列腺切除术和憩室切除术标本报告数据集：国际癌症报告合作组织（ICCR）的建议。
Virchows Arch. 2020 Apr;476(4):521-534. doi: 10.1007/s00428-019-02727-1. Epub 2020 Jan 8.
8
Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR).国际癌症报告协作组织（ICCR）关于泌尿道上皮癌活检和经尿道切除标本报告的数据集建议。
Mod Pathol. 2020 Apr;33(4):700-712. doi: 10.1038/s41379-019-0403-9. Epub 2019 Nov 4.
9
What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review.膀胱癌的尿路上皮和非尿路上皮组织学变异对肌层浸润性和转移性膀胱癌患者的肿瘤学结局的预测价值及临床重要性如何？欧洲泌尿外科学会肌层浸润性和转移性膀胱癌指南小组系统评价。
Eur Urol Oncol. 2019 Nov;2(6):625-642. doi: 10.1016/j.euo.2019.09.003. Epub 2019 Oct 8.
10
What Is the Significance of Variant Histology in Urothelial Carcinoma?尿路上皮癌中变异组织学的意义是什么？
Eur Urol Focus. 2020 Jul 15;6(4):653-663. doi: 10.1016/j.euf.2019.09.003. Epub 2019 Sep 15.